Jair Bar

9.8k total citations
152 papers, 2.6k citations indexed

About

Jair Bar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jair Bar has authored 152 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 93 papers in Pulmonary and Respiratory Medicine and 28 papers in Cancer Research. Recurrent topics in Jair Bar's work include Lung Cancer Treatments and Mutations (76 papers), Lung Cancer Diagnosis and Treatment (39 papers) and Lung Cancer Research Studies (35 papers). Jair Bar is often cited by papers focused on Lung Cancer Treatments and Mutations (76 papers), Lung Cancer Diagnosis and Treatment (39 papers) and Lung Cancer Research Studies (35 papers). Jair Bar collaborates with scholars based in Israel, United States and Canada. Jair Bar's co-authors include Amir Onn, Moshe Oren, Damien Urban, Neta Moskovits, Nir Peled, Iris Kamer, Elizabeth Dudnik, Teodor Gottfried, Sameh Daher and Alona Zer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jair Bar

145 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jair Bar Israel	28	1.5k	992	832	504	349	152	2.6k
Fei Zhou China	31	1.9k 1.3×	1.7k 1.8×	885 1.1×	597 1.2×	376 1.1×	122	3.3k
Amanda J. Redig United States	22	1.5k 1.0×	1.5k 1.5×	1.2k 1.4×	648 1.3×	222 0.6×	39	3.1k
Akhil Chawla United States	13	1.9k 1.3×	570 0.6×	614 0.7×	638 1.3×	558 1.6×	44	2.5k
Ana C. Garrido-Castro United States	12	1.4k 1.0×	502 0.5×	649 0.8×	474 0.9×	287 0.8×	54	2.2k
Takahiro Oike Japan	26	1.3k 0.9×	740 0.7×	1.3k 1.6×	360 0.7×	644 1.8×	113	2.9k
Jianxin Xue China	29	815 0.6×	787 0.8×	796 1.0×	427 0.8×	347 1.0×	143	2.3k
Daniel G. Stover United States	26	1.5k 1.0×	658 0.7×	1.3k 1.5×	783 1.6×	373 1.1×	148	3.1k
Christopher D. Willey United States	28	777 0.5×	528 0.5×	1.2k 1.5×	366 0.7×	349 1.0×	118	2.5k
Saranya Chumsri United States	31	2.1k 1.4×	588 0.6×	1.3k 1.5×	1.0k 2.0×	628 1.8×	125	3.8k
Xin Ye China	17	1.8k 1.2×	731 0.7×	2.0k 2.5×	851 1.7×	518 1.5×	77	3.7k

Countries citing papers authored by Jair Bar

Since Specialization

Citations

This map shows the geographic impact of Jair Bar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jair Bar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jair Bar more than expected).

Fields of papers citing papers by Jair Bar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jair Bar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jair Bar. The network helps show where Jair Bar may publish in the future.

Co-authorship network of co-authors of Jair Bar

This figure shows the co-authorship network connecting the top 25 collaborators of Jair Bar. A scholar is included among the top collaborators of Jair Bar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jair Bar. Jair Bar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shalata, Walid, Jair Bar, Mor Moskovitz, et al.. (2025). Lurbinectedin for extensive stage − small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes. Lung Cancer. 205. 108598–108598. 1 indexed citations

Eisenberg, Vasyl, Iris Kamer, Jair Bar, et al.. (2024). Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells. Cancer Immunology Research. 12(10). 1380–1391. 3 indexed citations

Pérol, M., Kōichi Goto, Benjamin Solomon, et al.. (2024). Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.. Journal of Clinical Oncology. 42(16_suppl). 8547–8547.

Moraes, Francisco Cézar Aquino de, Ludimila Cavalcante, Yu Fujiwara, et al.. (2024). Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.. Journal of Clinical Oncology. 42(16_suppl). 8642–8642. 2 indexed citations

Fujiwara, Yu, Francisco Cézar Aquino de Moraes, Natasha B. Leighl, et al.. (2024). Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. JCO Precision Oncology. 8(8). e2400331–e2400331. 4 indexed citations

Chandana, Sreenivasa R, Noura J. Choudhury, Afshin Dowlati, et al.. (2024). First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3001–3001. 10 indexed citations

Pérol, M., Benjamin Solomon, Kōichi Goto, et al.. (2024). CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer. Journal of Clinical Oncology. 42(21). 2500–2505. 5 indexed citations

Bar, Jair, Shobhit Baijal, Weidong Zhao, et al.. (2023). 1397P Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort. Annals of Oncology. 34. S799–S800. 2 indexed citations

Babu, Sunil, Shunsuke Kondo, Alexander I. Spira, et al.. (2023). 1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors. Annals of Oncology. 34. S647–S648. 2 indexed citations

10.

Moskovitz, Mor, Sivan Shamai, Barliz Waissengrin, et al.. (2023). P2.07-09 Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO?. Journal of Thoracic Oncology. 18(11). S327–S327. 1 indexed citations

11.

Cohen, Merav, Amir Giladi, Oren Barboy, et al.. (2022). The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nature Cancer. 3(3). 303–317. 117 indexed citations

12.

Bar, Jair, Damien Urban, Uri Amit, et al.. (2021). Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades. Journal of Oncology. 2021. 1–10. 25 indexed citations

13.

Moskovitz, Mor, Damien Urban, Hovav Nechushtan, et al.. (2021). dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%. Clinical Lung Cancer. 23(2). 122–134. 17 indexed citations

14.

Kamer, Iris, Elizabeta Bab-Dinitz, Gili Perry, et al.. (2020). Stromal-MDM2 Promotes Lung Cancer Cell Invasion through Tumor–Host Feedback Signaling. Molecular Cancer Research. 18(6). 926–937. 9 indexed citations

15.

Ofek, Efrat, Jair Bar, Nadia Prisant, et al.. (2020). MiR-21, EGFR and PTEN in non-small cell lung cancer: an in situ hybridisation and immunohistochemistry study. Journal of Clinical Pathology. 73(10). 636–641. 16 indexed citations

16.

Peled, Michael, Jair Bar, Sumit Chatterji, et al.. (2020). Early Blood-based Liquid Biopsy in Patients with Treatment-naïve Metastatic Adenocarcinoma of the Lung: A Case Series.. PubMed. 22(12). 784–787. 2 indexed citations

17.

Eshet, Yael, Erez N. Baruch, Ronnie Shapira‐Frommer, et al.. (2018). Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study. Cancer Immunology Research. 6(12). 1453–1458. 46 indexed citations

18.

Romaniello, Donatella, Luigi Mazzeo, Maicol Mancini, et al.. (2018). A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clinical Cancer Research. 24(22). 5610–5621. 43 indexed citations

19.

Bar, Jair, et al.. (2017). Investigating of Immunotherapy and Combination Treatments in Ex-Vivo Culture Model of NSCLC. Journal of Thoracic Oncology. 12(8). S1538–S1538. 1 indexed citations

20.

Appel, Sarit, Yaacov Richard Lawrence, Raphael M. Pfeffer, et al.. (2017). Stereotactic Ablative Body Radiation for Stage I Lung Cancer in Israel: A Retrospective Single-Center Report.. PubMed. 19(1). 39–43. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact